Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (NASDAQ: PSNL) is a Fremont, California-based medical laboratories company focused on advanced genomics for precision oncology. The Personalis news stream centers on developments in molecular residual disease (MRD) testing, circulating tumor DNA (ctDNA) analysis, and ultra-comprehensive genomic profiling for cancer management.
News about Personalis often highlights clinical and scientific milestones for its NeXT Personal MRD platform, including publications in journals such as Clinical Cancer Research, Cell, Nature Medicine, and Annals of Oncology as referenced in company communications. These articles describe how NeXT Personal is used to detect very small traces of ctDNA, monitor treatment response, and predict outcomes across solid tumors, including breast cancer and non-small cell lung cancer.
Investors and clinicians following PSNL can expect updates on Medicare coverage decisions for NeXT Personal tests, reimbursement rate determinations, and coverage expansions for indications such as breast cancer surveillance. Press releases also cover collaborations with biopharma companies and academic centers, including trials like TRACERx, NeoADAURA, and LAURA, where Personalis’ assays are applied to assess residual disease, relapse risk, and therapy response.
Additional news items include quarterly and annual financial results, preliminary performance updates, and disclosures related to the company’s "Win-in-MRD" commercial strategy and clinical test volume trends. Corporate announcements such as participation in healthcare conferences, inducement equity grants under Nasdaq rules, and amendments to commercialization agreements with partners like Tempus AI, Inc. are also part of the PSNL news flow.
By reviewing Personalis news, readers can track how the company’s MRD and precision oncology platforms are being adopted in clinical practice and research, as well as monitor key regulatory, reimbursement, and partnership developments that shape its role in cancer genomics.
Personalis (Nasdaq: PSNL) said its management team will attend the TD Cowen 46th Annual Healthcare Conference on March 3, 2026 at the Boston Marriott Copley Place in Boston, MA.
The appearance is a management attendance at a sector conference and does not announce new financial or clinical data.
Personalis (Nasdaq: PSNL) will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. The company will host a conference call and live webcast the same day at 2:00 p.m. PT / 5:00 p.m. ET to discuss results and recent highlights.
Investors can join by phone (877-451-6152 domestic; 201-389-0879 international) or watch the live webinar via the Events section at investors.personalis.com. A replay will be archived on the website after the call.
Personalis (Nasdaq: PSNL) announced that Medicare will cover its NeXT Personal molecular residual disease (MRD) test for surveillance of Stage I–III non-small cell lung cancer. Coverage is supported by data from the TRACERx collaboration, with results published in Cell, and expands access for Medicare beneficiaries.
The test uses whole-genome sequencing and tracks up to ~1800 mutations to detect trace circulating tumor DNA (ctDNA) for earlier recurrence surveillance.
Personalis (Nasdaq: PSNL) announced a publication in npj Precision Oncology on the NeXT Personal® MRD assay for ultrasensitive ctDNA monitoring of immunotherapy response across advanced solid tumors.
Interim analysis of 39 patients (nine tumor types) showed median 23 days to molecular response, 161 days lead time over imaging for progression, detection of ctDNA using up to ~1,800 tumor variants, 33% of positives in the ultrasensitive range (<100 PPM), and ctDNA clearance linked to 7x higher overall survival.
Personalis (Nasdaq: PSNL) said its management team will attend the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026 at Cliff Lodge in Snowbird, Utah.
This is a public investor conference appearance where management will meet investors and industry participants.
Personalis (Nasdaq: PSNL) launched Real-Time Variant Tracker, an early-access option for its ultrasensitive NeXT Personal molecular residual disease (MRD) blood test.
The Tracker adds optional reporting of emerging resistance and therapeutically targetable mutations, including ESR1 and hundreds of other clinically relevant mutations across solid tumors, to inform treatment decisions during MRD monitoring and surveillance. The option is available to physicians and biopharma partners through an Early Access Program (EAP).
Personalis (Nasdaq: PSNL) reported preliminary unaudited results for the year ended December 31, 2025, highlighting clinical and commercial progress and a strong cash position. Total 2025 revenue is expected to be $69.0M to $70.0M versus $84.6M in 2024. Clinical test volume reached ~16,233 tests in 2025 (≈+400% YoY) with clinical test revenue of ~$2.0M. Q4 revenue is preliminarily $17.0M to $18.0M, with Q4 clinical volume of 6,183 tests (+41% sequential) and clinical revenue ≈$0.9M. Core commercial streams (pharma/services/other) contributed ~$49M–$50M, and enterprise/population sequencing revenue totaled ≈$18.0M. The company ended 2025 with approximately $240.0M in cash, including ≈$109.0M net proceeds from an ATM program. Medicare coverage for breast cancer surveillance and peer‑reviewed publications were noted as strategic clinical milestones.
Personalis (Nasdaq: PSNL) announced publication of a study in Clinical Cancer Research demonstrating clinical utility of its NeXT Personal ultrasensitive, tumor-informed MRD ctDNA assay for monitoring immunotherapy across solid tumors.
The study analyzed 202 stage IV patients across 24 cancer types, tracking up to ~1,800 tumor-specific variants per patient. Key findings: baseline ctDNA detected in 98% of patients; early decreases in ctDNA were associated with significantly higher overall survival, while early increases correlated with a 0% overall response rate; and durable ctDNA clearance (negative for ≥180 days) corresponded to 100% overall survival in the cohort.
Personalis (Nasdaq: PSNL) announced a Cell publication reporting results from 431 stage I–III NSCLC patients in the TRACERx cohort, tracked a median of >5 years using the NeXT Personal ultrasensitive MRD test.
Key findings: the test showed exceptional sensitivity and specificity across diagnosis, post-surgery landmark, adjuvant therapy, and long-term surveillance; ~36–43% of detections were in the ultrasensitive range; cancer was detected a median of ~5–9 months (up to ~57 months) before imaging; failure to clear ctDNA during adjuvant chemo was associated with >5x higher relapse risk. The test uses whole-genome sequencing and proprietary noise suppression to detect ctDNA down to ~1 PPM.
Personalis (Nasdaq: PSNL) announced its management team will attend the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 at the Lotte New York Palace in New York, NY.
The company will be represented by management at the conference to engage with investors and industry participants.